Premium
The ralationship between changes in 5‐HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
Author(s) -
Orr MW,
Boullin DJ
Publication year - 1976
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1976.tb00648.x
Subject(s) - fluphenazine , chlorpromazine , platelet aggregation , psychopathology , platelet , medicine , schizophrenia (object oriented programming) , population , extrapyramidal symptoms , pharmacology , endocrinology , psychiatry , haloperidol , antipsychotic , dopamine , environmental health
Platelet aggregation responses to 5‐HT and adenosine diphosphate were examined in a population of eighteen patients treated with fluphenazine decanoate for longer than one year. 5‐HT induced aggregation was enhanced in ten subjects. This enhancement was similar to that previously described in patients receiving chlorpromazine. Patients who showed enhanced 5‐HT induced aggregation showed less rateable psychopathology and less extrapyramidal side‐effects than patients who did not show enhancement. These findings suggest that platelet aggregation responses could be used to identify patients who could be safely withdrawn from long‐term neuroleptic therapy.